Get the content you want anytime you want.
REGISTER NOW | SIGN IN
ARTICLE

Top 5 Contagion® News Articles for the Week of June 11, 2017

JUN 17, 2017 | CONTAGION® EDITORIAL STAFF

#5: Gilead Submits NDA for HIV Combo Therapy & More New Antibiotics Show Positive Results in Trials: Business Watch Report 

This week’s Contagion® Business Watch Report includes the latest on Gilead’s new drug application (NDA) for their fixed-dose combination treatment, results of Janssen’s Phase 2b Trial for pimodivir, access to data presented at ASM Microbe 2017 from Spero Therapeutics on their new antibiotics, new product enhancements released by Clorox, and news that TECHLAB has received FDA 510(K) clearance to market their E. HISTOLYTICA QUIK CHEK™ Test.
 
Read the full report here.
 

#4: The Scary Reality Behind WHO's Updated Essential Medicines List 

On Tuesday, June 6, 2017, the World Health Organization (WHO) announced a revision to their Essential Medicines List (EML). The EML has been around for roughly 40 years and has several sections; however, this announcement marked the biggest revision for the antibiotic section.  

Currently in its 20th edition, the previous edition of the EML was released in 2015. Each EML includes two sections—one for adults and one for children. The WHO Model List of Essential Medicines (or EML) is considered a core list of the most basic medicines needed for a healthcare system to meet the minimum needs for basic patient are. The purpose of the EML is truly to provide a laundry list of medicines that are required for basic patient care and the WHO takes care to prioritize them according to efficacy, safety, and cost-effectiveness. The list is also developed based on priority health conditions that “are selected on the basis of current and estimated future public health relevance.”
 
More on the implications of the updated EML is available here


FEATURED
Although researchers have made huge strides in finding effective treatments, a preventative vaccine remains elusive.
x